Adapting Critical Time Intervention to Support Inpatient Medical Care Transition Read more about Adapting Critical Time Intervention to Support Inpatient Medical Care Transition
The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients Read more about The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients
A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease Read more about A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) Read more about Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) Read more about Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients Read more about CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors Read more about Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors
Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder Read more about Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder
Corrona Inflammatory Bowel Disease (IBD) Registry Read more about Corrona Inflammatory Bowel Disease (IBD) Registry
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer Read more about Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer